Defective recovery of QT dispersion following transcatheter aortic valve implantation: frequency, predictors and prognosis

Rutger-Jan Nuis1, Gokhan Turgut2, Robert M van der Boon1, Nicolas M van Mieghem1, Sjoerd T Nauta1, Patrick W Serruys1, Ron T van Domburg3, Giulio Zuchelli4, Luc Jordaens2, Peter P de Jaegere1

1 Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands  
2 Department of Electrophysiology, Erasmus Thoraxcenter, Rotterdam, the Netherlands  
3 Department of Biostatistics, Erasmus Thoraxcenter, Rotterdam, the Netherlands  
4 Division of Cardiovascular Diseases, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Abstract

Background Corrected QT dispersion (cQTD) has been correlated with non-uniform ventricular repolarisation and increased mortality. In patients with aortic stenosis, cQTD has been shown improved after surgical valve replacement, but the effects of transcatheter aortic valve implantation (TAVI) are unknown. Therefore, we sought to explore the frequency, predictors and prognostic effects of defective cQTD recovery at 6 months after TAVI.

Methods A total of 222 patients underwent TAVI with the Medtronic-CoreValve System between November 2005 and January 2012. Patients who were on class I or III antiarrhythmics or on chronic haemodialysis or who developed atrial fibrillation, a new bundle branch block or became pacemaker dependent after TAVI were excluded. As a result, pre-, post- and follow-up ECG (median: 6 months) analysis was available in 45 eligible patients. Defective cQTD recovery was defined as any progression beyond the baseline cQTD at 6 months.

Results In the 45 patients, the mean cQTD was 47 ± 23 ms at baseline, 45 ± 17 ms immediately after TAVI and 40 ± 16 ms at 6 months (15% reduction, \( P = 0.049 \)). Compared to baseline, cQTD at 6 months was improved in 60% of the patients whereas defective cQTD recovery was present in 40%. cQTD increase immediately after TAVI was an independent predictor of defective cQTD recovery at 6 months (per 10 ms increase; OR: 1.89, 95% CI: 1.15–3.12). By univariable analysis, defective cQTD recovery was associated with late mortality (HR: 1.52, 95% CI: 1.05–2.17).

Conclusions Despite a gradual reduction of cQTD after TAVI, 40% of the patients had defective recovery at 6 months which was associated with late mortality. More detailed ECG analysis after TAVI may help to avoid late death.

J Geriatr Cardiol 2015; 12: 482–488. doi:10.11909/j.issn.1671-5411.2015.05.016

Keywords: Aortic stenosis; Conduction abnormalities; Left bundle branch block; Predictors; QT dispersion; Transcatheter aortic valve implantation

1 Introduction

The natural course of aortic stenosis (AS) is characterised by among others cardiac arrhythmia and sudden death in up to 34% of the patients.\(^1\)\(^–\)\(^3\) Surgical aortic valve replacement (AVR) has shown to reduce the risk of sudden death.\(^3\) Whether this also holds for patients who undergo transcatheter aortic valve implantation (TAVI), which are characterised by more advanced age and co-morbid conditions than patients who undergo AVR, remains to be elucidated. Consistent with the findings of Thomas, et al.,\(^4\) we recently found that sudden death accounts for approximately 10% of all-cause 1-year mortality after TAVI.\(^5\)

Although not per se cardiac in origin, it is conceivable that late sudden death may be explained or caused by abnormalities in ventricular repolarisation. Corrected QT dispersion (cQTD) can be used to assess disturbances in the homogeneity of ventricular repolarisation and may, therefore, help to identify patients who are at increased risk of unexplained late death.\(^6\) An increased cQTD reflects inhomogeneity of ventricular repolarisation and is associated with an increased risk of cardiac death in patients with a variety of heart diseases.\(^6\)\(^–\)\(^9\)
A reduction in cQTD has been reported early after AVR most likely due to a reduction in afterload, improved coronary flow and early left ventricular mass regression. Similar effects may be expected after TAVI, yet, as mentioned these patients are older with more comorbidities and may also have been exposed to a longer period of increased left ventricular afterload. We, therefore, sought to explore the changes in cQTD and the frequency, predictors and prognostic effects of defective cQTD recovery at six months after TAVI.

2 Methods

2.1 Patients and procedure

Between November 2005 and January 2012, a total of 222 consecutive patients with AS underwent trans-arterial TAVI with the Medtronic CoreValve System (MCS). In all patients, a pre-, post- and follow-up 12-lead ECG was available. Patients with atrial fibrillation and those taking class I or III antiarrhythmics or on chronic haemodialysis were excluded. For the purpose of an accurate assessment of cQTD changes over time, patients with a new conduction abnormality [left bundle branch block (LBBB), right bundle branch block (RBBB), or paced rhythm] immediately or six months after TAVI and those with a pre-existent conduction abnormality that progressed to a higher degree AV block were excluded as well. The final study population, therefore, consisted of 45 patients (Figure 1).

Details of the patient selection, prosthesis and subsequent phases of the transfemoral TAVI procedure have been previously published. Briefly, all patients referred for TAVI were first seen on the out-patient clinic and then discussed in the heart team. Treatment decision was based upon consensus between an interventional cardiologist and a cardiac surgeon and since September 2010 by a team consisting of an interventional cardiologist, cardiac surgeon and a clinical cardiologist and/or an echocardiographist. Treatment decision was based upon a weighted assessment of risk and benefit of the various treatment modalities on the basis of all clinical and technical information of the patient. The procedure was performed with the patient under general anaesthesia with a temporary pacemaker wire positioned in the right ventricle and with default femoral arterial access through an 18F sheath. The aortic valve was first crossed under fluoroscopic control using a straight wire. This wire was exchanged for a stiff support wire followed by balloon valvuloplasty (22 or 23 mm × 4 cm) under rapid right ventricular pacing. The valve (available in 26, 29 and 31 mm) was then advanced over the aortic arch into the aortic annulus with a target deployment of 4–6 mm below the annulus.

![Figure 1. Flow diagram of ECGs available for serial analysis of pre-, post- and 6 month ECGs.](http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology)
wave to the TP baseline. When a T wave was complicated by a U wave, the end of the T wave was defined as the nadir between the T and the U waves.[13] Intervals preceded by premature beats were not measured. For each lead, wherever possible, three consecutive cycles were measured and corrected for the heart rate using the Bazett’s formula.[19,20] The average of the three consecutive cycles was used. The cJT interval for each interval was calculated by subtracting the QRS interval from the cQT interval.[21]

cQTD was calculated by measuring the cQT interval of all 12 ECG leads and defined by the substraction of the shortest from the longest interval (maximum minus minimum cQT interval).[6] In case of uncertainty of the definition of the end of a T wave, the lead disclosing this uncertainty was excluded from analysis. At least nine measurable leads were required for the purpose of this study. No attempt was made to correct for missing leads.[22] Defective cQTD recovery was defined as any progression beyond the baseline cQTD as assessed using follow-up ECGs. The cQTD variation (ΔcQTD) was calculated as the difference between cQTD before vs. after and before vs. 6 months after TAVI.[23]

Left and right bundle branch block was defined according to the World Health Organization and International Society and Federation for Cardiology Task Force.[24]

2.3 Follow-up

Follow-up information was collected during structured out-patient clinic visits after discharge. Survival and cause of death was obtained every 6 months by contacting the Dutch Civil Register and/or referring cardiologists and/or the general practitioners. Sudden and unexpected death was defined as a natural, unexpected death due to cardiac causes, heralded by an abrupt loss of consciousness within 1 h of the onset of acute symptoms in patients who were previously stable.[8]

2.4 Statistical analysis

Categorical variables are presented as frequencies and percentages and were compared with the Chi square test or Fisher’s exact test. The normality of distributions was assessed with the Shapiro-Wilk test. Normal and skewed continuous variables are presented as means ± SD and medians [interquartile range (IQR)], respectively. The Wilcoxon signed-rank test (for continuous variables) and the McNemar test conducted by exact methods (for categorical variables) were used to perform paired comparisons for pre-treatment vs. post-treatment and pre-treatment vs. follow-up ECG findings. Multivariable logistic regression including all variables with $P < 0.05$ in the univariable analysis was performed to determine the predictive factors of defective cQTD recovery. Given the small number of deaths during follow-up ($n = 7$), a univariable Cox regression analysis was performed to explore the potential association between defective cQTD recovery and late mortality. A two-sided $P < 0.05$ was considered to indicate significance and all statistical analyses were performed with SPSS software (version 17).

In accordance with the institutions policies, every patient gave written informed consent for TAVI and the use of anonymous clinical, procedural and follow-up data for research in accordance with Institutional Review Board approval. This study complies with the Declaration of Helsinki.

3 Results

The baseline characteristics and the serial ECG changes are summarized in Table 1 and 2, respectively. Overall, the

| Table 1. Baseline characteristics of patients undergoing TAVI ($n = 45$). |
|-----------------|-----------------|
| Age, yr         | 78 ± 10         |
| Men             | 26 (58)         |
| Body mass index, kg/m² | 25.8 ± 3.8      |
| New York Heart Association class ≥ III | 37 (82)         |
| Previous cerebrovascular event | 12 (27)         |
| Previous myocardial infarction | 7 (16)         |
| Previous coronary artery bypass graft surgery | 13 (29)         |
| History of heart failure | 18 (40)         |
| Syncope | 5 (11)         |
| Diabetes mellitus | 9 (20)         |
| Hypertension | 27 (60)         |
| Peripheral vascular disease | 5 (11)         |
| Chronic obstructive pulmonary disease | 16 (36)         |
| Logistic EuroSCORE | 12 (9–22)      |
| Laboratory |
| Serum sodium, mmol/L | 141 ± 3         |
| Serum potassium, mmol/L | 4.4 ± 0.6       |
| Serum creatinine, mmol/L | 88 (77–112)     |
| Medication |
| Beta-blockers | 22 (49)         |
| Digoxin | 1 (2)         |
| Diuretics | 23 (51)         |
| Angiotensin converting enzyme inhibitors | 13 (29)         |
| Echocardiography |
| Left ventricular ejection fraction, % | 50 ± 13         |
| Aortic valve area, cm² | 0.69 ± 0.2      |
| Peak gradient, mmHg | 75.27          |
| Mitral regurgitation grade III or greater | 3 (7)          |
| Aortic regurgitation grade III or greater | 7 (16)         |

Data are expressed as means ± SD, medians (IQR) or numbers (%). TAVI: transcatheter aortic valve implantation; IQR: interquartile range.
Table 2. Serial analyses of pre- post- and at follow-up ECGs after TAVI.

|                        | Pre-treatment | Post-treatment | follow-up | $P$-value | $P$-value |
|------------------------|---------------|----------------|-----------|-----------|-----------|
|                        |               |                |           |           |           |
| Entire cohort, $n = 45$ |               |                |           |           |           |
| Heart rate, beats/min  | 70 ± 12       | 75 ± 13        | 72 ± 12   | 0.004     | 0.29      |
| PR interval, ms        | 182 ± 28      | 188 ± 32       | 180 ± 23  | 0.33      | 0.74      |
| QRS width, ms         | 124 ± 31      | 127 ± 31       | 124 ± 33  | 0.045     | 0.69      |
| cJT interval, ms      |               |                |           |           |           |
| Minimum                | 285 ± 31      | 285 ± 24       | 287 ± 26  | 0.89      | 0.92      |
| Maximum                | 332 ± 25      | 330 ± 25       | 327 ± 26  | 0.58      | 0.12      |
| cQT interval, ms      |               |                |           |           |           |
| Minimum                | 417 ± 40      | 427 ± 36       | 422 ± 40  | 0.049     | 0.24      |
| Maximum                | 464 ± 33      | 471 ± 35       | 462 ± 41  | 0.091     | 0.68      |
| Dispersion             | 47 ± 23       | 45 ± 17        | 40 ± 16   | 0.82      | 0.049     |
| Patients without conduction abnormalities, $n = 27$ |               |                |           |           |           |
| Heart rate beats/min  | 70 ± 14       | 74 ± 15        | 72 ± 13   | 0.051     | 0.48      |
| PR interval, ms        | 183 ± 30      | 186 ± 34       | 177 ± 26  | 0.88      | 0.21      |
| QRS width, ms         | 100 ± 8       | 105 ± 16       | 100 ± 10  | 0.045     | 0.92      |
| cJT interval, ms      |               |                |           |           |           |
| Minimum                | 287 ± 33      | 287 ± 27       | 290 ± 27  | 0.64      | 0.86      |
| Maximum                | 338 ± 23      | 334 ± 28       | 328 ± 25  | 0.27      | 0.052     |
| Dispersion             | 47 ± 23       | 45 ± 17        | 40 ± 16   | 0.82      | 0.049     |

Data are expressed as means ± SD, medians (IQR) or $n$ (%). TAVI: transcatheter aortic valve implantation; IQR: interquartile range.

average heart rate, QRS duration and minimum cQT interval increased immediately after TAVI, yet all changes returned to baseline values at 6 months. The cQTD decreased immediately after TAVI, with a further decline at 6 months (47 vs. 45 vs. 40 ms, $P = 0.049$). In a subgroup of 27 patients without conduction abnormality before, after and 6 months after TAVI, the cQTD decreased from 50 ms at baseline to 38 ms at 6 months (reduction of 24%, $P = 0.006$).

3.1 Frequency and predictors of defective cQTD recovery

In 27 out of the 45 patients (60%), a reduction in cQTD between baseline and follow-up was observed, whereas in 18 patients (40%) an increase was observed (defective cQTD recovery). The individual changes in cQTD are presented in Figure 2. Details of the baseline characteristics and perioperative results grouped according to the occurrence of defective cQTD recovery are shown in Table 3 and 4, respectively.

Patients with defective cQTD recovery had a worse ejection fraction (45% vs. 54%, $P = 0.026$), longer minimum cQT interval before TAVI (432 ms vs. 407 ms, $P = 0.001$) and an increase in cQTD immediately after TAVI ($\Delta$cQTD: +13 ms vs. −13 ms, $P = 0.002$) in comparison to patients without defective cQTD recovery. The independent predictors of defective cQTD recovery are listed in Table 5.

3.2 Prognostic effects of defective cQTD recovery

The median follow-up was 14 months (IQR: 7–23); seven patients (16%) died at a median of 11 months (IQR: 6–15) after TAVI. Four deaths occurred in patients with defective cQTD recovery (cardiac death: 50%) and three deaths in patients without defective cQTD recovery (cardiac death: 0%). By univariable analysis, a higher baseline serum creatinine (per 10 mmol/L increase, HR: 1.09; 95% CI: 1.03–1.16) and defective cQTD recovery ($\Delta$cQTD at 6 months, per 10 ms decrease, HR: 1.52; 95% CI: 1.05–2.17) were significantly associated with late mortality.

---

Figure 2. Individual changes in cQTD during follow-up according to the occurrence of defective cQTD recovery. cQTD: corrected QT dispersion.

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology
4 Discussion

In this study of 45 patients with aortic stenosis, we found that the average cQTD-time was significantly reduced at 6 months after TAVI. Yet, defective cQTD recovery was present in 40% of the patients. Worsening of cQTD immediately after TAVI was an independent predictor of defective cQTD recovery at 6 months, which in turn showed a directional signal of a higher risk of late mortality.

cQTD can be used to determine non-uniform ventricular repolarization and is increased in a variety of cardiac conditions such as long QT syndrome, chronic heart failure, hypertrophic cardiomyopathy, myocardial infarction and in patients with left ventricular hypertrophy associated with aortic stenosis.[6–9] In these patients, increased cQTD has been associated with susceptibility to ventricular arrhythmias, cardiac mortality and unexplained sudden death.[17] Yet, in patients with aortic stenosis, cQTD has been shown to reduce early after surgical aortic valve replacement, which is attributed to a reduced afterload, improved coronary flow and early left ventricular mass regression.[10–12]
Table 5. Independent predictors of defective cQTD recovery after TAVI.

| Variable                                | Crude OR (95% CI) | Adjusted OR (95% CI) | P    |
|-----------------------------------------|-------------------|----------------------|------|
| Left ventricular ejection fraction (per 10% decrease) | 1.78 (1.04–3.03)   | 1.61 (0.84–3.09)     | 0.15 |
| Pre-operative minimum cQT interval (per 10 ms increase) | 1.20 (1.00–1.42)   | 1.12 (0.91–1.39)     | 0.28 |
| cQTD variation (pre vs. post)            | 1.98              | 1.89                 | 0.012|
| (per 10 ms decrease)                     | (1.25–3.14)       | (1.15–3.12)          |      |

cQTD: corrected QT dispersion; TAVI: transcatheter aortic valve implantation.

This has also been demonstrated in patients with severe congenital AS undergoing percutaneous balloon valvuloplasty.\cite{25}

The findings of the present study indicate that cQTD recovery after TAVI does not occur immediately after the procedure but is a time related phenomenon that is not complete at 6 months (40% of the patients still had a defective cQTD recovery). This is in contrast with the findings of Sarubbi, et al.\cite{25} who showed a 23% cQTD reduction immediately after balloon valvuloplasty and those of Tsai, et al.\cite{11} who demonstrated a 48% reduction by 6 days after AVR.

The evident and immediate cQTD reduction following AVR contrasts with our findings of a delayed and incomplete cQTD reduction after TAVI. This can be explained by patient-related factors since TAVI patients are in general older than patients who undergo surgical valve replacement and, therefore, have more pronounced age-related degenerative changes of the myocardium. In addition, TAVI patients may suffer from longer periods of elevated afterload in comparison to surgical patients due to a longer time interval to clinical detection and treatment delay.\cite{26,27} They may therefore, have more extensive cQTD and less response to early changes following afterload correction.

The observed increase in cQTD immediately after TAVI in patients with a defective cQTD recovery during follow-up could be due to an early impairment of the conductive system not appearing at the 12-lead ECG evaluation. In these particular patients, the reduction in afterload, improved coronary flow and left ventricular mass regression may not be sufficient to improve the cQTD at follow-up. This phenomenon could be particularly common after CoreValve implantation considering the frequent occurrence of new conduction defects associated with this device.\cite{16}

The latter may also explain why a significant number of patients had discordant cQTD changes (i.e., an initial decrease in cQTD from baseline to post-TAVI, followed by an increase at follow-up), which occurred in 46% of patients.

The prognostic value of cQTD is subject of debate.\cite{17} Yet, some studies demonstrated that cQTD is strongly associated with malignant arrhythmias and cardiac mortality.\cite{16,18}

As mentioned, cQTD recovery was incomplete at six months in the present population. Although we lack the power to demonstrate an association with malignant arrhythmia and sudden cardiac death, it is conceivable that these patients are at increased risk of late sudden death. Of note, the causes of death in patients with defective cQTD recovery were sudden death (n = 1), myocardial infarction (n = 1) and terminal kidney failure (n = 2), whereas patients without defective cQTD recovery died because of a pneumonia (n = 1), sepsis (n = 1) and a perforated diverticulitis (n = 1). The clinical relevance of defective cQTD recovery was previously demonstrated by Chalil, et al.\cite{28} who demonstrated that increased cQTD duration independently predicts sudden death/resuscitation in patients undergoing cardiac resynchronization therapy.

4.1 Limitations

cQTD is known to be an approximate of repolarisation abnormalities. Yet, given the absence of an underlying pathophysiologic explanation, the observation of (defective) cQTD recovery is of observational nature. We also acknowledge the fact that drugs other than class I or III antiarrhythmic drugs (i.e., antidepressants) may have affected the cQTD recovery assessment and the fact that only quarter of the patients who underwent TAVI were eligible mainly because of the frequent occurrence of new conduction abnormalities associated with TAVI. Another limitation of the present study is that it cannot indicate which measures have to be taken in case of defective cQTD recovery. The question is whether one should first stop all drugs that may have such an effect or whether one even should consider the implantation of an automated implantable cardioverter-defibrillator.

Data in larger series of patients stemming from multicenter observations are needed to confirm or to rule out the current observations, the precise timing and/or delay of recovery and to elucidate the role of potential measures to be taken. At last, the inter- and intra-observer variability of approximately 20% should be taken into account when interpreting the study results, and warrants future research to confirm our findings.

4.2 Conclusions

TAVI was associated with a gradual reduction of cQTD during the follow-up period. Defective cQTD recovery was seen in 40% of the patients. This was predominantly seen in patients with an increase in cQTD immediately after TAVI and was associated with a higher risk of late mortality. In addition to the regular follow-up examinations after TAVI, it is conceivable that more detailed analysis of the ECG may help to identify patients at risk of late unexpected death.
Acknowledgements

Maarten van Ettinger and Marcel de Wijs are acknowledged for their technical support.

References

1  Chizner MA, Pearle DL, deLeon AC, Jr. The natural history of aortic stenosis in adults. Am Heart J 1980; 99: 419–424.
2  Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect. Results of 24-hour ECG monitoring. Circulation 1993; 87: 189–1101.
3  Keane JF, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 1993; 87: 116–127.
4  Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2011; 124: 425–433.
5  Van Mieghem N, Van der Boon R, Nuis RJ, et al. Cause of death after transcatheter aortic valve implantation. Cath Cardiovasc Intv 2014; 83: 277–282.
6  Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342–344.
7  Glancy JM, Garratt CJ, Woods KL, et al. QT dispersion and mortality after myocardial infarction. Lancet 1995; 345: 945–948.
8  Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327–329.
9  Zoghi M, Gurgun C, Yavuzgil O, et al. QT dispersion in patients with different etiologies of left ventricular hypertrophy: the significance of QT dispersion in endurance athletes. Int J Cardiol 2002; 84: 153–159.
10 Darbar D, Cherry CJ, Kerins DM. QT dispersion is reduced after valve replacement in patients with aortic stenosis. Heart 1999; 82: 15–18.
11 Tsai CH, Lee TM, Su SF. Regression of ventricular repolarisation inhomogeneity after aortic bileaflet valve replacement in patients with aortic stenosis. Int J Cardiol 1999; 70: 141–148.
12 Christakis GT, Joyner CD, Morgan CD, et al. Left ventricular mass regression early after aortic valve replacement. Ann Thorac Surg 1996; 62: 1084–1089.
13 Brendorp B, Elming H, Jun L, et al. QT dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation 2001; 103: 831–835.
14 Otten AM, van Domburg RT, van Gamaeran M, et al. Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve replacement. EuroIntervention 2008; 4: 250–255.
15 de Jaegere P, van Dijk LC, Laborde JC, et al. True percutaneous implantation of the CoreValve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar(R) XL and the TandemHeart(R). EuroIntervention 2007; 2: 500–505.
16 Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve System in patients with aortic stenosis. Eur Heart J 2011; 32: 2067–2074.
17 Coumel P, Maisonneuve P, Badilini F. Dispersion of ventricular repolarization: reality? Illusion? Significance? Circulation 1998; 97: 2491–2493.
18 Murray A, McLaughlin NB, Bourke JP, et al. Errors in manual measurement of QT intervals. Br Heart J 1994; 71: 386–390.
19 Bazett HC. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol 1920; 53: 320–339.
20 Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61: 83–87.
21 Jordans LJ. The clinical value of QT dispersion: new perspectives on the assessment of cardiac repolarization more than 75 years after Bazett's formula. Europace 1999; 1: 73–76.
22 Hnatkova K, Malik M, Kautzner J, et al. Adjustment of QT dispersion assessed from 12 lead electrocardiograms for different numbers of analysed electrocardiographic leads: comparison of stability of different methods. Br Heart J 1994; 72: 390–396.
23 Zimario M, Corazzini A, Tataciore A, et al. Defective recovery of QT dispersion predicts late cardiac mortality after percutaneous coronary intervention. Heart 2011; 97: 466–472.
24 Willems JL, Robles de Medina EO, Bernard R, et al. Criteria for intraventricular conduction disturbances and pre-excitation. World Health Organizational/International Society and Federation for Cardiology Task Force Ad Hoc. J Am Coll Cardiol 1985; 5: 1261–1275.
25 Sarubbi B, Calvanese R, Cappelli Bigazzi M, et al. Electrophysiological changes following balloon valvuloplasty and angioplasty for aortic stenosis and coarctation of aorta: clinical evidence for mechano-electrical feedback in humans. Int J Cardiol 2004; 93: 7–11.
26 Wenaweser P, Pilgrim T, Kadner A, et al. Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol 2011; 58: 2151–2162.
27 Saia F, Marrozzini C, Dall'Ara G, et al. How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation? J Cardiovasc Med 2010; 11: 727–732.
28 Chalil S, Yousef ZR, Muyhaldeen SA, et al. Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchronization therapy. J Am Coll Cardiol 2006; 47: 2486–2492.